Pilot Study: Fluvoxamine Treatment for Depression and Anxiety Disorders in Children and Adolescents with Cancer

Gothelf, Doron; Rubinstein, Maly; Shemesh, Eyal; Miller, O. M.; Farbstein, Ilana; Klein, Anat; Weizman, Abraham; Apter, Alan; Yaniv, Isaac

doi:10.1097/01.chi.0000181042.29208.eb

Cited by 46 publications

(26 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A cautionary note is that for children, the use of SSRIs, as described in the FDA's ''black box'' warning, may be associated with an increase in suicidal ideation. An open trial [28] suggested the safety and efficacy of the SSRI fluvoxamine when given to children with cancer; fluvoxamine is the only SSRI studied in depressed children with cancer. At present, trauma-specific CBT techniques and, in selected cases, SSRIs are the best justified interventions for medically ill children who experience significant distress or impairment related to PTSD based on a growing, if incomplete, evidence base and with appropriate FDA-mandated precautions.…”

Section: Interventionsmentioning

confidence: 99%

Post-traumatic Stress Response to Life-Threatening Illnesses in Children and Their Parents

Stuber

Shemesh

2006

Child and Adolescent Psychiatric Clinics of North America

Self Cite

View full text Add to dashboard Cite

Section: Interventionsmentioning

confidence: 99%

Post-traumatic Stress Response to Life-Threatening Illnesses in Children and Their Parents

Stuber

Shemesh

2006

Child and Adolescent Psychiatric Clinics of North America

Self Cite

View full text Add to dashboard Cite

“…[4][5][6][7][8][9][10][11] The difficulty in identifying these symptoms may stem from both patient and physician factors. Physical symptoms associated with a psychiatric disorder may be attributed to the medical illness or treatment.…”

mentioning

confidence: 99%

Screening for Depression and Anxiety in Adolescent Cancer Patients

Kersun

Rourke

Mickley³

et al. 2009

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

The goals of this study were to evaluate the feasibility of depression and anxiety screening in on-therapy adolescents with cancer, determine the prevalence of depression and anxiety in this sample, and assess the concordance between patient and oncologist report of patient symptoms. Forty-one adolescents (ages 12 to 18 y) undergoing cancer therapy in an outpatient oncology clinic completed the Beck Youth Inventory II (BYI II) Depression and Anxiety scales. Treating oncologists independently rated patient depression and anxiety. Ninety-eight percent of patients agreed to participate and average time to measure completion was <15 minutes. Mean T-scores for the BDI-Y (Depression module) and BAI-Y (Anxiety module) for most were not different than published norms. Three and 2 patients scored in the moderate-extremely elevated range of the BAI-Y and BDI-Y, respectively. There were no associations between scores and sex, age, diagnosis, time since diagnosis, or treatment intensity. A depression and anxiety-screening program is feasible in the outpatient pediatric oncology setting. Rates of adolescent self-reported anxiety and depression are low, although oncologists perceived more patient distress. This is an area for future investigation.

show abstract

“…Data on antidepressant treatment specific to children with malignancies is lacking, though there are some small studies demonstrating that SSRIs are well tolerated and efficacious in children with cancer [28]. Moreover, there is evidence that pediatric oncologists frequently prescribe SSRIs for treatment of depression and anxiety [29,30].…”

Section: Depressed Moodmentioning

confidence: 99%